|
KWANGDONG PHARM is a pharmaceutical and food & beverage company established in 1963. The company operates through three main business segments: OTC pharmacy sales, ETC hospital sales, and F&B. Its OTC portfolio includes traditional Korean medicine products such as Ssanghwatang, Cheongsimwon, Gyeongokgo, and Gongjindan. The ETC segment covers prescription drugs, including vaccines, anticancer agents, and other specialty pharmaceuticals. The F&B segment features major brands like Vita 500, Jeju Samdasoo, corn silk tea, and hawthorn tea. The company serves the domestic market, with the majority of revenue generated from South Korea, and distributes products through pharmacies, hospitals, and retail channels. It maintains manufacturing facilities in Pyeongtaek and engages in research and development for new pharmaceuticals and functional foods. KWANGDONG PHARM has established partnerships with global pharmaceutical companies for co-promotion and license-in agreements to expand its specialty drug portfolio. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage ekdp.com |
| Sector Healthcare | IR page — | |
|
Tags
traditional korean medicine, vaccines, vitamin c drinks, functional beverages, specialty pharmaceuticals, healthcare, otc drugs, etcs, food and beverage, pharmaceutical manufacturing, Ssanghwatang, Cheongsimwon, Gyeongokgo, Gongjindan, Vita 500, Jeju Samdasoo, Corn Silk Tea, Hawthorn Tea, Bion, Cofolang, Sunkist, Benitol, Prito, Cetraxal Plus, Revocovi, Mycapssa, Myalept, Juxtapid, Filsuvez, Brimochol, Raxone, Elfabrio, Lamzede, NVK002, ATB-346, Vyleesi, KD101, KD-BMT-301, OCU-400
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 581.263B |
| Market cap (USD) | $ 427.8M |
| P/E | 23.11 |
| PEG | — |
| P/BV | 0.91 |
| P/S | 0.34 |
| P/OCF | 32.87 |
| P/FCF | 118.92 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 3.4% |
| ROI | 3.2% |
| ROIC | 3.3% |
| Profit margin | 1.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | -4.6% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | -6.7% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.66T | 1.641T | 1.514T | 1.432T | 1.338T | 1.244T | 1.238T | 1.18T | 1.142T | 1.056T | 955.454B | 522.274B | 468.385B |
| Net profit | 20.968B | 40.481B | 36.966B | 24.174B | 24.019B | 45.37B | 23.058B | 22.345B | 23.196B | 28.063B | 35.015B | 35.044B | 22.037B |
| Free cash flow | 57.145B | -87.883B | -46.515B | 37.539B | 31.145B | 17.566B | 16.648B | 34.27B | 9.391B | 10.655B | 14.116B | 14.335B | 27.504B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 213B | 228B | 215B | 236B | 257B | 242B | 228B | 263B | 318B | 281B |
| ↳ YoY growth | -5.8% | +6.8% | -5.6% | +9.6% | +8.6% | -5.7% | -5.8% | +15.4% | +20.9% | -11.6% |
| ↳ 5y CAGR | +20.8% | +22.7% | +2.5% | +2.5% | 0.0% | +4.1% | +6.1% | +1.8% | ||
| Borrowings, current (KRW) | 70.9B | 99.6B | 86.3B | 85.5B | 94.1B | — | 114B | 214B | 215B | 239B |
| Borrowings, non-current (KRW) | 29B | 10.7B | 15.3B | 26.7B | 15.6B | — | 23.6B | 21.7B | 74.5B | 67.4B |
| Cash and deposits (KRW) | 42.7B | 47.6B | 67.5B | 76.3B | 54.9B | 84B | 104B | 77.3B | 116B | 141B |
| Intangible assets (KRW) | 28.3B | 27.3B | 21.7B | 16.4B | 12.4B | 16.7B | 16.1B | 36.7B | 37.6B | 49.2B |
| Net debt (borrowings + leases - cash) (KRW) | -13.7B | 62.7B | 34.1B | 35.9B | 54.8B | — | 34.5B | 158B | 173B | 165B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 28.8B | 23.5B | 53.1B | 29.3B | 22.8B | 54.9B | 62.8B | -11.7B | -12.2B | 82.3B |
| Purchases of property, plant and equipment (KRW) | -18.1B | -14.1B | -18.8B | -12.6B | -5.26B | -23.8B | -25.3B | -34.8B | -75.7B | -25.2B |
| Purchases of intangible assets (KRW) | 0.00 | -4.02B | -318M | -45M | -40.8M | -652M | -657M | -373M | -2.06B | -1.18B |
| Dividends paid (cash effect) (KRW) | -3.25B | -3.25B | -3.25B | -3.21B | -3.17B | -4.11B | -4.11B | -4.11B | -4.01B | -3.93B |
| Share buybacks (cash effect) (KRW) | 0.00 | 0.00 | -2.79B | -4.32B | 0.00 | — | 0.00 | -6.23B | -4.07B | -364M |
| Interest paid (cash effect) (KRW) | -2.6B | -2.44B | -2.77B | -3.17B | -2.53B | -2.37B | -3.75B | -7.51B | -11.7B | -10.6B |
| Income taxes paid (cash effect) (KRW) | -16.7B | -12.4B | -13B | -12.5B | -14.2B | -11.4B | -13.7B | -10.4B | -13.6B | -8.78B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | 10.7B | 5.37B | 34B | 16.6B | 17.5B | 30.5B | 36.9B | -46.9B | -89.9B | 56B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 25.5B | 20B | 19.6B | 24.1B | 49B | 29.2B | 23.9B | 40.2B | 41.5B | 20.1B |
| Comprehensive income to owners (KRW) | 25.8B | 20.4B | 20B | 24.4B | 49B | 25.6B | 22.2B | 37.6B | 39.8B | 19.1B |
| Reported | Nov 14, 2017 | Mar 29, 2019 | Mar 29, 2019 | Mar 30, 2020 | Apr 5, 2021 | Mar 22, 2024 | Mar 25, 2025 | Mar 25, 2025 | Mar 25, 2025 | Mar 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding KWANGDONG PHARM
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
